Palatin Technologies (PTN) Corporate presentation summary

Technology platform and therapeutic focus

• Specializes in melanocortin system targeting for obesity, rare MC4R diseases, and inflammatory/autoimmune conditions.

• First to gain FDA approval for a melanocortin agent (Vyleesi® for female sexual dysfunction).

• Leverages expertise in melanocortin biology and chemistry for multiple therapeutic opportunities.

Leadership and team

• Leadership team has extensive experience in drug research, development, finance, operations, and business development.

• Key executives have backgrounds from major pharma companies and decades of industry experience.

MC4R obesity programs and pipeline

• Developing next-generation MC4R agonists: oral small molecule (PL7737) and once-weekly peptide for rare MC4R pathway diseases (HO, PWS).

• PL7737 granted FDA orphan drug designation for obesity due to leptin receptor deficiency.

• PL7737 shows significant, dose-dependent weight loss in preclinical models without hyperpigmentation.

• IND submission for PL7737 planned for 1H 2026; Phase 1 and 2/3 studies in HO and PWS patients targeted for late 2026.

• Once-weekly peptide agonist IND enabling studies planned for 2H 2026, with clinical studies in 2027.